Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441357 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL851229 | 0.87 | TAS1R3 (0.40) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL3018642 | 0.87 | TAS1R3 (0.40) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL15135131 | 0.81 | RAB9A (0.55) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL1455906 | 0.80 | TRPA1 (0.39) | RAB9ANPC1HPGDKDM4EGLA | |
| SCHEMBL1455905 | 0.80 | TRPA1 (0.39) | RAB9ANPC1HPGDKDM4EGLA | |
| SCHEMBL25865289 | 0.80 | TAS1R3 (0.43) | RAB9ANPC1HPGDALDH1A1KDM4E | |
| SCHEMBL411326 | 0.77 | PTGS1 (0.49) | RAB9ANPC1HPGDKDM4ETSHR | |
| SCHEMBL15081451 | 0.76 | SLC6A3 (0.63) | SMN1; SMN2HPGDALDH1A1KDM4EGLA | |
| SCHEMBL18660861 | 0.76 | PPARG (0.49) | SMN1; SMN2HPGDALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738632-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-08-22 | — | — | US | disclosed |
| US-9738632-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-08-22 | — | — | US | disclosed |
| US-9738632-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-08-22 | — | — | US | disclosed |
| US-20170081315-A1 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081315-A1 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081315-A1 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-9512110-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2016-12-06 | — | — | US | disclosed |
| US-9512110-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2016-12-06 | — | — | US | disclosed |
| US-9512110-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2016-12-06 | — | — | US | disclosed |
| EP-2291369-B1 | BENZODIOXINYL SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-20100087489-A1 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-08 | — | — | US | disclosed |
| WO-2009142571-A1 | PHENYL AND BENZODIOXINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009142571-A1 | PHENYL AND BENZODIOXINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | disclosed |
| EP-2097384-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | AstraZeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008063116-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | SMN1; SMN2 4640/4885RAB9A 1785/4885NPC1 30/4885 |
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | SMN1; SMN2 4085/4885RAB9A 2317/4885NPC1 1476/4885 |
| US-20100087489-A1 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives | CYP3A5, ABCB1, CYP4X1 | SMN1; SMN2 4778/4885RAB9A 3489/4885NPC1 249/4885 |
| US-20170081315-A1 | Phenyl and benzodioxinyl substituted indazoles derivatives | CYP3A5, ABCB1, CYP4X1 | SMN1; SMN2 4778/4885RAB9A 3489/4885NPC1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.